Risk factors for prostate cancer

Nature Clinical Practice Urology

Volumn 6, Issue 2, 2009, Pages 87-95

  Patel, Amit R ^a   Klein, Eric A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; HEREDITY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; UNITED STATES;

AGE FACTORS; ANDROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 60149092906     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1290     Document Type: Review

References (78)

1. Coleman MP et al. (2008) Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol 9: 730-756
2. Nelen V (2007) Epidemiology of prostate cancer. Recent Results Cancer Res 175: 1-8
3. Grönberg H (2003) Prostate cancer epidemiology. Lancet 361 859-864
4. Sakr WA et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385
5. Hankey BF et al. (1999) Cancer surveillance series: Interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024
6. Potosky AL et al. (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552
7. Lilja H et al. (2007) Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25: 431-436
8. Quinn M and Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: Individual countries. BJU Int 90: 174-184
9. Woolf CM (1960) An investigation of the familial aspects of carcinoma of the prostate. Cancer 13: 739-744
10. Eeles RA et al. (1997) Familial prostate cancer: The evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 79 (suppl 1): 8-14
11. Bratt O (2002) Hereditary prostate cancer: Clinical aspects. J Urol 168: 906-913
12. Carter BS et al. (1993) Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 150: 797-802
13. Carter BS et al. (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89: 3367-3371
14. Grönberg H et al. (1994) Studies of genetic factors in prostate cancer in a twin population. J Urol 152: 1484-1487
15. Page WF et al. (1997) Heredity and prostate cancer: A study of World War II veteran twins. Prostate 33: 240-245
16. Gillanders EM et al. (2004) Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 96: 1240-1247
17. Klein EA and Silverman R (2008) Inflammation, infection, and prostate cancer. Curr Opin Urol 18: 315-319
18. Amundadottir LT et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652-658
19. Zheng SL et al. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358: 910-919
20. Xu J et al. (2008) Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 14: 5819-5824
21. Ellinger J et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161-167
22. Petrovics G et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847-3852
23. Oikawa T and Yamada T (2003) Molecular biology of the ETS family of transcription factors. Gene 303: 11-34
24. Tomlins SA et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648
25. Perner S et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341
26. Morris DS et al. (2008) The discovery and application of gene fusions in prostate cancer. BJU Int 102: 276-282
27. Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420: 860-867
28. Platz EA and De Marzo AM (2004) Epidemiology of inflammation and prostate cancer. J Urol 171 (2 suppl): S36-S40
29. Dennis LK et al. (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78-83
30. Dennis LK and Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13: 72-79
31. Sarma AV et al. (2006) Sexual behavior, sexually transmitted diseases and prostatitis: The risk of prostate cancer in black men. J Urol 176: 1108-1113
32. Sutcliffe S et al. (2006) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2160-2166
33. Sutcliffe S et al. (2007) Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 16: 1573-1580
34. De Marzo AM et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269
35. Casey G et al. (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32: 581-583
36. Larson BT et al. (2008) Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 179: 1344-1348
37. Urisman A et al. (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2: E25
38. Hsing AW (2001) Hormones and prostate cancer: What's next? Epidemiol Rev 23: 42-58
39. Gann PH et al. (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126
40. Eaton NE et al. (1999) Endogenous sex hormones and prostate cancer: A quantitative review of prospective studies. Br J Cancer 80: 930-934
41. Roddam AW et al. (2008) Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100: 170-183
42. Jaffe JM et al. (2000) Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 60 1626-1630
43. Makridakis NM et al. (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978
44. Pearce CL et al. (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: Lessons learned. Hum Mol Genet 17: 2456-2461
45. Scariano JK et al. (2008) The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate 68: 1798-1805
46. Setiawan VW et al. (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 16: 2237-2246
47. Sarma AV et al. (2008) Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate 68 296-305
48. Neslund-Dudas C et al. (2007) SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67: 1654-1663
49. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224
50. Lucia MS et al. (2007) Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 1375-1383
51. Redman MW et al. (2008) Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 1: 174-181
52. Bostwick DG et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490
53. Muir CS et al. (1991) The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol 30: 133-140
54. Shimizu H et al. (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963-966
55. Kaaks R et al. (2000) Plasma androgens, IGF-1, body size, and prostate cancer risk: A synthetic review. Prostate Cancer Prostatic Dis 3: 157-172
56. Nelson WG et al. (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172 (5 suppl): S6-S11
57. Clinton SK et al. (1988) The combined effects of dietary protein and fat intake during the promotion phase of 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats. J Nutr 118: 1577-1585
58. Wang Y et al. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a lowfat diet. J Natl Cancer Inst 87: 1456-1462
59. Aronson WJ et al. (1999) Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 35: 130-136
60. MacInnis RJ and English DR (2006) Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control 17: 989-1003
61. Gong Z et al. (2006) Obesity, diabetes, and risk of prostate cancer: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 15: 1977-1983
62. Han JH et al. (2008) Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology 72: 749-754
63. Freedland S et al. (2008) Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 72: 1102-1105
64. Kasper JS and Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056-2062
65. Leitzmann MF et al. (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19: 1267-1276
66. Frankenberry KA et al. (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188: 560-565
67. Somasundar P et al. (2004) Leptin is a growth factor in cancer. J Surg Res 116: 337-349
68. Hsing AW et al. (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86: 843S-857S
69. Ribeiro R et al. (2004) Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59: 268-274
70. Giovannucci E et al. (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85: 1571-1579
71. Hayes RB et al. (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8: 25-34
72. Oakley-Girvan I et al. (2004) Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 13: 1325-1330
73. Lippman SM et al. (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97: 94-102
74. Lippman SM et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51
75. Sesso HD et al. (2001) Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol 30: 749-755
76. Schoonen WM et al. (2005) Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113: 133-140
77. Ewings P and Bowie C (1996) A case-control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 74: 661-666
78. Giles GG et al. (2003) Sexual factors and prostate cancer. BJU Int 92: 211-216